Mr. Sina Habibi reports

COGNETIVITY NEUROSCIENCES ANNOUNCES COMMERCIAL AGREEMENT WITH MEDICLINIC TO PROVIDE COGNITIVE ASSESSMENT TO OVER 50S

Cognetivity Neurosciences Ltd. has arranged a collaboration with the Mediclinic Group, a prominent international private hospital group operating across Europe, the Middle East and southern Africa. This pivotal partnership will start in the United Arab Emirates and is set to revolutionize brain health diagnosis and care in the region, effectively addressing the escalating concern around Alzheimer's disease and other cognitive health issues. Under this commercial engagement, Cognetivity's state-of-the-art cognitive assessment platform, Cognica, will be seamlessly integrated into Mediclinic's health care services. Cognica harnesses the power of artificial intelligence (AI) and machine learning to deliver rapid, accurate and non-invasive cognitive assessments, allowing accurate, early detection of brain health issues. This strategic partnership underscores the commitment of both Cognetivity and Mediclinic to take a pro-active stance against the rising challenges around brain health.

The collaboration will roll out in a phased approach, commencing with the inclusion of Cognica into Mediclinic's healthy aging program. This initial phase empowers family medicine doctors, geriatricians and neurologists across select clinics and hospitals to conduct cognitive screenings on individuals aged 50 and above. By identifying cognitive impairments early on, interventions are much more effective, and this initiative aligns with Mediclinic's dedication to preventative care, promoting optimal patient well-being and quality of life.

As the engagement progresses, Cognica will further enhance Mediclinic's cognitive diagnostic pathway, facilitating precise evaluations and tailored recommendations by neurologists. Additionally, the partnership will extend to the clinical services of Park View Hospital, expanding the reach of cognitive screening and monitoring to a diverse patient population and improving patient outcomes in this rapidly growing at-risk group.

"Through this strategic partnership, Cognetivity and Mediclinic are reshaping the landscape of brain health care in the UAE," commented Mazen Sobh, vice-president of commercial development at Cognetivity. "Our joint effort leverages technological innovation and medical expertise to drive impactful change in how cognitive health is diagnosed and managed. Cognica's unique attributes are ideal for the delivery of effective, early detection of brain health issues and we look forward to expanding our work with Mediclinic as we move forwards."

Willie Willemse, chief strategy officer at Mediclinic Middle East, echoed the sentiment, saying: "This collaboration signifies Mediclinic's commitment to advancing patient care in the UAE. By integrating Cognica, we are embracing a pro-active approach to cognitive health, ensuring that our patients receive the highest standard of care and support."

This strategic partnership represents a significant step toward addressing the growing challenge of cognitive health disorders in the United Arab Emirates, emphasizing the commitment of both organizations to improving patient outcomes and overall quality of life.

Cognetivity's mission is to utilize its AI platform technology to transform the landscape of brain health globally, enhance the quality of care provided to patients and to reduce the burden and cost to providers and payers, delivering the company's vision of a brighter mind for a fuller life.

About Cognetivity Neurosciences Ltd.

Cognetivity is a technology company that has developed a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity's Cognica uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. Cognica is currently available for clinical use in the United States, United Kingdom, Europe, Canada and the Middle East, with regulatory approval in other regions expected later in 2023.

We seek Safe Harbor.